Labcorp Dividend and Market Update: Key Information Before Ex-dividend Date May 29, 2025
Generado por agente de IAAinvest Dividend Digest
domingo, 25 de mayo de 2025, 7:11 pm ET1 min de lectura
LH--
Labcorp has announced a dividend of $0.720 per share, with the ex-dividend date set for May 29, 2025, and payment scheduled for Jun 11, 2025. This latest dividend is higher than the average of the last ten dividends, which stood at $0.398 per share. The announcement was made on Apr 10, 2025. This cash dividend follows the company's prior payout on Mar 12, 2025, which also distributed $0.720 per share.
Recently, LabcorpLH-- has been the focus of considerable attention due to several significant developments. The company secured a $117.03 million contract modification for clinical reference laboratoryLAB-- testing services, continuing its collaboration with the U.S. Army Health Contracting Activity. This project is expected to run until Dec 31, 2025, and highlights Labcorp's strong position within the healthcare sector.
In addition, Labcorp's stock has seen a 16% increase in share price over the past month, partially attributed to its partnership with Frame, aimed at enhancing fertility solutions. Analysts have offered one-year price targets ranging from $248.00 to $300.00, with an average target price of $274.07, implying a potential upside from the current price of $242.53. The consensus recommendation from brokerage firms rates Labcorp as "Outperform," reflecting confidence in its growth prospects.
Furthermore, Labcorp's fundamentals remain robust, with the company paying out just 21% of its free cash flow in dividends last year, indicating a sustainable dividend policy. Analysts have recently noted Labcorp's withdrawal of its 2020 guidance and suspension of share buyback activities, decisions shaped by the impact of the coronavirus on first-quarter results.
The ex-dividend date of May 29, 2025, is crucial for investors, as it marks the deadline for purchasing Labcorp stock to receive the upcoming dividend. Any acquisitions made after this date will not qualify for the dividend payout.
Recently, LabcorpLH-- has been the focus of considerable attention due to several significant developments. The company secured a $117.03 million contract modification for clinical reference laboratoryLAB-- testing services, continuing its collaboration with the U.S. Army Health Contracting Activity. This project is expected to run until Dec 31, 2025, and highlights Labcorp's strong position within the healthcare sector.
In addition, Labcorp's stock has seen a 16% increase in share price over the past month, partially attributed to its partnership with Frame, aimed at enhancing fertility solutions. Analysts have offered one-year price targets ranging from $248.00 to $300.00, with an average target price of $274.07, implying a potential upside from the current price of $242.53. The consensus recommendation from brokerage firms rates Labcorp as "Outperform," reflecting confidence in its growth prospects.
Furthermore, Labcorp's fundamentals remain robust, with the company paying out just 21% of its free cash flow in dividends last year, indicating a sustainable dividend policy. Analysts have recently noted Labcorp's withdrawal of its 2020 guidance and suspension of share buyback activities, decisions shaped by the impact of the coronavirus on first-quarter results.
The ex-dividend date of May 29, 2025, is crucial for investors, as it marks the deadline for purchasing Labcorp stock to receive the upcoming dividend. Any acquisitions made after this date will not qualify for the dividend payout.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios